Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 5/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.52 |
| ▸ | TSHR | P16473 | 4/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.52 |
| ▸ | HPGD | P15428 | 5/20 | 0.45 |
| ▸ | HSP90AA1 | P07900 | 4/20 | 0.45 |
| ▸ | MAPT | P10636 | 3/20 | 0.45 |
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | HSPA5 | P11021 | 2/20 | 0.45 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.45 |
| ▸ | TTR | P02766 | 1/20 | 0.45 |
| ▸ | PGR | P06401 | 1/20 | 0.45 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.45 |
| ▸ | CBR1 | P16152 | 1/20 | 0.45 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.45 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.45 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.45 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.45 |
| ▸ | ERN1 | O75460 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29954084 | 1.00 | HSD17B10 (0.52) | HSD17B10ALDH1A1TSHRCYP3A4TDP1 | |
| SCHEMBL320185 | 0.81 | HSD17B10 (0.52) | HSD17B10ALDH1A1TSHRCYP3A4TDP1 | |
| SCHEMBL31112067 | 0.81 | HSD17B10 (0.52) | HSD17B10ALDH1A1TSHRCYP3A4TDP1 | |
| SCHEMBL29375771 | 0.78 | TSHR (0.48) | HSD17B10ALDH1A1TSHRCYP3A4TDP1 | |
| SCHEMBL41990 | 0.78 | TSHR (0.48) | HSD17B10ALDH1A1TSHRCYP3A4TDP1 | |
| SCHEMBL25365977 | 0.77 | CYP2A6 (0.43) | HSD17B10ALDH1A1TSHRCYP3A4TDP1 | |
| SCHEMBL25363704 | 0.77 | CYP2A6 (0.43) | HSD17B10ALDH1A1TSHRCYP3A4TDP1 | |
| SCHEMBL25459961 | 0.77 | HPGD (0.40) | HSD17B10ALDH1A1TSHRCYP3A4TDP1 | |
| SCHEMBL624402 | 0.76 | CYP3A4 (0.43) | HSD17B10ALDH1A1TSHRCYP3A4TDP1 | |
| SCHEMBL29825793 | 0.76 | CYP3A4 (0.43) | HSD17B10ALDH1A1TSHRCYP3A4TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 121 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118515534-B | Multi-tooth ligand, multi-tooth ligand metal catalyst, and preparation method and application thereof | 华南理工大学 | 2024-11-05 | — | — | CN | claimed |
| CN-118515534-A | Multi-tooth ligand, multi-tooth ligand metal catalyst, and preparation method and application thereof | 华南理工大学 | 2024-08-20 | — | — | CN | claimed |
| US-20250340563-A1 | FUSED PYRIDAZINE DERIVATIVES AS NLRP3 INHIBITORS | TAKEDA DEVELOPMENT CENTER AMERICAS, INC. | 2025-11-06 | — | — | US | disclosed |
| EP-4644380-A1 | PYRIDAZINE NLRP3 INHIBITOR COMPOUND, PHARMACEUTICAL COMPOSITION, AND PREPARATION METHOD THEREFOR AND USE THEREOF | Changchun Genescience Pharmaceutical Co., Ltd. (CN) | 2025-11-05 | — | — | EP | disclosed |
| EP-4446327-B1 | COMPOUND AND ORGANIC LIGHT-EMITTING ELEMENT COMPRISING SAME | LG CHEMICAL LTD (KR) | 2025-09-24 | — | — | EP | disclosed |
| US-12421209-B2 | Compounds | HOFFMANN-LA ROCHE INC. (US) | 2025-09-23 | — | — | US | disclosed |
| EP-4254527-B1 | ORGANIC LIGHT EMITTING DEVICE | LG CHEMICAL LTD (KR) | 2025-07-30 | — | — | EP | disclosed |
| EP-3832746-B1 | ORGANIC LIGHT EMITTING DEVICE | LG CHEMICAL LTD (KR) | 2025-07-09 | — | — | EP | disclosed |
| US-20250160207-A1 | COMPOUND AND ORGANIC LIGHT-EMITTING ELEMENT COMPRISING SAME | LG CHEM, LTD. (KR) | 2025-05-15 | — | — | US | disclosed |
| CN-119907802-A | Pyrrolotriazine and imidazotriazine derivatives as modulators of NLRP3 inflammatory small body pathways | AC免疫有限公司 | 2025-04-29 | — | — | CN | disclosed |
| US-20250084092-A1 | ANNULATED PYRIDAZINE COMPOUND | NICO THERAPEUTICS, INC. | 2025-03-13 | — | — | US | disclosed |
| US-20130150339-A1 | Bicyclic Aryl and Heteroaryl Sodium Channel Inhibitors | AMGEN INC. (US) | 2013-06-13 | — | — | US | disclosed |
| US-20130150339-A1 | Bicyclic Aryl and Heteroaryl Sodium Channel Inhibitors | AMGEN INC. (US) | 2013-06-13 | — | — | US | disclosed |
| EP-2566868-A1 | PYRROLO [3, 2 -D]PYRIMIDIN-3 -YL DERIVATIVES USED AS ACTIVATORS OF AMPK | GlaxoSmithKline LLC (US) | 2013-03-13 | — | — | EP | disclosed |
| US-20130053407-A1 | PYRROLO [3,2-D] PYRIMIDIN-3-YL DERIVATIVES USED AS ACTIVATORS OF AMPK | GLAXOSMITHKLINE LLC (US) | 2013-02-28 | — | — | US | disclosed |
| US-20120136023-A1 | Inhibitors of HIV Replication | VIIV HEALTHCARE UK LIMITED (GB) | 2012-05-31 | — | — | US | disclosed |
| US-20120136023-A1 | Inhibitors of HIV Replication | VIIV HEALTHCARE UK LIMITED (GB) | 2012-05-31 | — | — | US | disclosed |
| US-20120136023-A1 | Inhibitors of HIV Replication | VIIV HEALTHCARE UK LIMITED (GB) | 2012-05-31 | — | — | US | disclosed |
| WO-2012066442-A1 | INHIBITORS OF HIV REPLICATION | PFIZER LIMITED (GB) | 2012-05-24 | — | — | WO | disclosed |
| WO-2011138307-A1 | PYRROLO [3, 2 -D] PYRIMIDIN-3 -YL DERIVATIVES USED AS ACTIVATORS OF AMPK | GLAXOSMITHKLINE LLC (US) | 2011-11-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12421209-B2 | Compounds | C5, RB1, RPS4X | HSD17B10 2005/4885ALDH1A1 1504/4885TSHR 1143/4885 |
| US-20120136023-A1 | Inhibitors of HIV Replication | RTF2, POLRMT, MAVS | HSD17B10 2965/4885ALDH1A1 4304/4885TSHR 4798/4885 |
| US-20130150339-A1 | Bicyclic Aryl and Heteroaryl Sodium Channel Inhibitors | SCN1A, SCN1B, CACNA1B | HSD17B10 941/4885ALDH1A1 795/4885TSHR 3969/4885 |
| US-20250160207-A1 | COMPOUND AND ORGANIC LIGHT-EMITTING ELEMENT COMPRISING SAME | LEF1, CRY1, CYP1A1 | HSD17B10 1869/4885ALDH1A1 28/4885TSHR 4566/4885 |
| US-20250340563-A1 | FUSED PYRIDAZINE DERIVATIVES AS NLRP3 INHIBITORS | NLRP3, NLRP1, NOD1 | HSD17B10 3539/4885ALDH1A1 1853/4885TSHR 2887/4885 |
| US-20250084092-A1 | ANNULATED PYRIDAZINE COMPOUND | NLRP3, NLRP1, PYCARD | HSD17B10 3210/4885ALDH1A1 1219/4885TSHR 4598/4885 |
| US-20130053407-A1 | PYRROLO [3,2-D] PYRIMIDIN-3-YL DERIVATIVES USED AS ACTIVATORS OF AMPK | PRKAG2, PRKAB2, PRKAG3 | HSD17B10 2053/4885ALDH1A1 1451/4885TSHR 2557/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.